Oculus Announces Creation of Subsidiary for Anti-Infective Drug Assets

Oculus Innovative Sciences, Inc. OCLS, today announced it has initiated the process to create a wholly owned subsidiary that will hold the company's anti-infective drug assets. The company recently announced, that based upon market research, there appeared to be a significant opportunity for a new drug utilizing the Microcyn® Technology for surgical suite use. The company's new surgical formulation has been finalized and the company is now preparing the clinical strategy in preparation for discussions with the FDA.